Evidence map›Paper›PMID 40242978›Full record

ArticleOncology reports2025

KLC3 activates PI3K/AKT signaling and promotes ovarian cancer cell proliferation and migration through COL3A1.

Jing Yang, Rongxia He, Xiaoling Zhang, Xing Wang, Min Liu, Xiaolong Liu, Yulan Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jing Yang *The First School of Clinical Medical, Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
Rongxia He *Department of Obstetrics, Lanzhou University Second Hospital, Lanzhou, Gansu 730000, P.R. China.
Xiaoling ZhangDepartment of Pathology, Gansu Provincial Hospital, Lanzhou, Gansu 730000, P.R. China.
Xing WangThe First School of Clinical Medical, Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
Min LiuDepartment of Obstetrics, Lanzhou University Second Hospital, Lanzhou, Gansu 730000, P.R. China.
Xiaolong LiuThe First School of Clinical Medical, Lanzhou University, Lanzhou, Gansu 730000, P.R. China.
Yulan LiThe First School of Clinical Medical, Lanzhou University, Lanzhou, Gansu 730000, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer (OC) is a prevalent malignancy; however, the role of kinesin light chain 3 (KLC3) in OC remains unclear. The present study conducted a comprehensive investigation of KLC3 using bioinformatics analysis, as well as

Indexed as

Collagen Type IIIMicrotubule-Associated ProteinsOvarian NeoplasmsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktAnimalsCell Line, TumorCell MovementCell ProliferationEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansKinesinsMiceMiddle AgedCOL3A1 protein, humanCollagen Type IIIKinesinsKlc3 protein, mouseMicrotubule-Associated ProteinsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktcollagen type III α1kinesin light chain 3ovarian cancerPI3K/AKT signaling pathway

Identifiers

PMID40242978
PMCPMC12046943

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.